News
Phastar’s B Corp certification affirms its status as a force for good organization
Phastar, a global specialist biometrics contract research organization (CRO), has become a certified B Corporation®. It comes after a stringent 12-month review to ensure protocols and procedures reflect the company’s commitment to high environment, social, and governance (EGS) standards.
Certified...
BioPharma
Overcoming Treatment Challenges With Cell And Gene Therapies
Gene and cell therapies have the potential to revolutionize healthcare by reprogramming the immune system to treat diseases that are difficult to address with traditional medicine. These therapies involve introducing, replacing, or deactivating genes in cells, either inside or...
News
New PAT – Based Strategy Stops Membrane Fouling In SP – TFF
A recent article published in the Journal of Membrane Science presents a new approach for implementing a robust single-pass tangential flow filtration (SP-TFF) operation in biomanufacturing. The authors introduce a process analytical technology (PAT)-based strategy that integrates and continuously...
Drug Research
Innovative Antibody Creation Requires An Apt CDMO Choice
Making the right contract development and manufacturing choice happens to be a pivotal decision for biopharmaceutical firms that happen to be embarking on projects pertaining to novel antibody development.
With the sector’s rising demand when it comes to qualified multidisciplinary...
BioPharma
Boosting Innovation And Value In UK Biopharma And Medtech
New recommendations from Imperial College London aim to boost competitiveness in the UK's biopharma and Medtech sectors. It assesses the value-added per capita in these sectors and provides insights into their needs, challenges, and opportunities. Technological solutions and policy...
Clinical Trials
BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate Therapy for Solid Tumors
BeiGene, a global biotechnology company, and DualityBio, a next-generation ADC company, announced an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC therapy for patients with select solid...
Clinical Trials
Velocity and Privia Health Enter Partnership to Embed Clinical Research Into Practice Sites
Velocity Clinical Research, the leading multi-specialty clinical sites business, and Privia Health, a physician enablement company serving more than 3,700 providers and 4.4 million patients, today announced a partnership to open embedded clinical research sites within Privia’s practice network.
The...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.